Laurent Servais

Researcher Next ID · RN-039840

Researcher · Biochemistry, Genetics and Molecular Biology

Liège, Belgium

Accepting doctoral researchersFunding unknown

Research interests

Biochemistry, Genetics and Molecular Biology

Medicine

Neuroscience

Neurogenetic and Muscular Disorders Research

Muscle Physiology and Disorders

Cardiomyopathy and Myosin Studies

RNA modifications and cancer

Genetic Neurodegenerative Diseases

Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Neuromuscular Disorders · 2021 · https://doi.org/10.1016/j.nmd.2021.03.007
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
The Lancet Neurology · 2021 · https://doi.org/10.1016/s1474-4422(21)00251-9
Risdiplam in Type 1 Spinal Muscular Atrophy
New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2009965
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
The Lancet Neurology · 2021 · https://doi.org/10.1016/s1474-4422(21)00367-7
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Neurology · 2020 · https://doi.org/10.1212/wnl.0000000000009233
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1702752
Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies
Medicine · 2014 · https://doi.org/10.1097/md.0000000000000028
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
The Lancet Neurology · 2014 · https://doi.org/10.1016/s1474-4422(14)70195-4

No projects listed.